NCT02357732View on ClinicalTrials.gov

Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

August 31, 2015

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions
Metastatic Melanoma
Interventions
DRUG

Nivolumab

DRUG

Trametinib

DRUG

Dabrafenib

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

University of Pittsburgh

OTHER

NCT02357732 - Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib | Biotech Hunter | Biotech Hunter